The pharmacological mechanism of action of Alpelisib-Piqray

Alpelisib (Piqray) is a new therapy approved for patients with HR-positive, HER2-negative breast cancer who have progressed on first-line hormone therapy. Apelix's novel mechanism selectively inhibits the PI3K pathway, a driver mutation found in HR-positive, HER2-negative breast cancer.

It is knownConstitutive activation of PI3K signaling is a critical step in mediating the transforming potential of oncogenes and tumor suppressors in many tumor types. In this pathway, the PIK3CA gene provides instructions for making the p110-alpha protein, a subunit of the PI3K enzyme. The p110-α protein is the catalytic subunit that performs the functions of PI3K. PI3K phosphorylates certain signaling molecules, triggering a series of additional reactions and transmitting signals within the cell. PI3K signaling is important for many cellular activities, including cell growth and proliferation, cell motility, production of new proteins, transport of intracellular materials, and cell survival.

Cancer-relatedChanges in the PI3K gene lead to driver gene mutations, leading to uncontrolled proliferation of cells, leading to the development of cancer. Resistance to multiple therapeutic interventions including chemotherapy, hormonal therapy, and anti-HER2 therapies may also be associated with constitutive activation of the PI3K pathway.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.